Nexplanon Removal: Subcutaneous vs. Topical Lidocaine

Augusta University

Status and phase: Unknown; Phase 4

Conditions: Contraception

Treatments: Drug: Eutectic Lidocaine Prilocaine; Drug: Subcutaneous Lidocaine

Study type: Interventional

Funder types: Other

Identifiers

NCT04467125

1288589-4

Details and patient eligibility

About

A randomized trial of using EMLA cream for anesthesia to remove Nexplanon versus the standard route of subcutaneous lidocaine for anesthesia. Primary endpoints are pain during procedure and time to removal.

Enrollment: 40 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Females with Nexplanon implant in place, desiring removal No allergy to lidocaine or any component of EMLA cream Age greater than or equal to 18years English as primary language Not pregnant

Exclusion criteria

• pregnant non-emglish speaking age less than 18 yo Allergy to lidocaine or EMLA

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

EMLA

Experimental group

Description:

Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.

Treatment:

Drug: Eutectic Lidocaine Prilocaine

Subcutaneous Lidocaine

Active Comparator group

Description:

Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal.

Treatment:

Drug: Subcutaneous Lidocaine